BioSpace News Archive

Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, announced it has closed a total of $50 million in financing from a Series C equity raise and the closing of a debt facility.

IPA, an artificial intelligence-driven biotherapeutic research and technology company, reported financial results for its second quarter of the 2024 fiscal year, which ended October 31, 2023.

CinFina Pharma, CinRx Pharma’s portfolio company dedicated to expanding treatment options for obesity and metabolic diseases, announced the scientific advisory board members for the company’s multi-asset pipeline.

Baxter International Inc., an innovative leader in infusion therapies and technologies, announced the completion of the first phase of its intravenous bag recycling program pilot.

Ensysce Biosciences, Inc., a clinical-stage company applying transformative chemistry to improve prescription drug safety, announced that its most recent study has demonstrated crucially important data for PF614 on pain intensity efficacy and speed of onset.

EXoPERT Corporation today announced the execution of a Sponsored Research Agreement with The University of Texas MD Anderson Cancer Center to support research with the goal of advancing the field of cancer detection and treatment by harnessing the capabilities of AI.

First Wave BioPharma, Inc. announced that the Company’s stockholders have approved all proposals voted on at the Company’s special meeting of stockholders held on December 12, 2023, and that its Board of Directors approved a 1-for-20 reverse stock split of its outstanding shares of common stock, to be effective as of 12:01 a.m. Eastern Time on Monday, December 18, 2023.

Medical and consumer genetics testing innovator and Imperial College London spin-out, DnaNudge, today announces that it has received approval from Ghana’s Food and Drugs Authority (FDA) to deliver its breakthrough four-in-one, respiratory viruses test for clinical deployment both inside and outside labs in the West African country.

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) (“NeuroSense”), a company developing treatments for severe neurodegenerative diseases, today reported additional positive efficacy data from further evaluation of its Phase 2b trial (PARADIGM) with NeuroSense’s lead drug candidate for amyotrophic lateral sclerosis (“ALS”), PrimeC.

The Lung Cancer Research Foundation® is pleased to announce the awardees of its 2023 Scientific Grant Program.